Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Scartozzi, Mario ^a   Bearzi, Italo ^a   Mandolesi, Alessandra ^a   Pierantoni, Chiara ^a   Loupakis, Fotios ^b   Zaniboni, Alberto ^c   Negri, Francesca ^d   Quadri, Antonello ^e   Zorzi, Fausto ^c   Galizia, Eva ^a   Berardi, Rossana ^a   Biscotti, Tommasina ^a   Labianca, Roberto ^e   Masi, Gianluca ^b   Falcone, Alfredo ^b   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Fondazione Poliambulanza   (Italy)

^d Dipartimento di Oncologia Medica   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; RAS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE COPY NUMBER; GENE NUMBER; GENETIC ANALYSIS; GENETIC PARAMETERS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MALE; ONCOGENE K RAS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WILD TYPE; COLORECTAL TUMOR; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 70049091759     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-303     Document Type: Article

References (21)

1. Goldberg RM Rothenberg ML Van Cutsem E Benson AB 3rd Blanke CD Diasio RB Grothey A Lenz HJ Meropol NJ Ramanathan RK Becerra CH Wickham R Armstrong D Viele C The Continuum of care: A Paradigm for management of metastatic colorectal cancer The Oncologist 2007, 12:38-50. 10.1634/ theoncologist.12-1-38 17227899
2. Jonker DJ O'Callaghan CJ Karapetis CS Zalcberg JR Tu D Au HJ Berry SR Krahn M Price T Simes RJ Tebbutt NC van Hazel G Wierzbicki R Langer C Moore MJ Cetuximab for the treatment of colorectal cancer J Clin Oncol 2007, 357:2040-7.
3. Cunningham D Humblet Y Siena S Khayat D Bleiberg H Santoro A Bets D Mueser M Harstrick A Verslype C Chau I Van Cutsem E Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 2004, 351:337-345. 10.1056/ NEJMoa033025 15269313
4. Sobrero AF Maurel J Fehrenbacher L Scheithauer W Abubakr YA Lutz MP Vega-Villegas ME Eng C Steinhauer EU Prausova J Lenz HJ Borg C Middleton G Kröning H Luppi G Kisker O Zubel A Langer C Kopit J Burris HA EPIC. Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 2008, 26:2311-2319. 10.1200/ JCO.2007.13.1193 18390971
5. Van Cutsem E Peeters M Siena S Humblet Y Hendlisz A Neyns B Canon JL Van Laethem JL Maurel J Richardson G Wolf M Amado RG Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 2007, 25:1658-1664. 10.1200/ JCO.2006.08.1620 17470858
6. Peeters M Wilson G Ducreux M Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results J Clin Oncol 2008, 26(suppl).
7. Van Cutsem E Kohne CH Hitre E Zaluski J Chang Chien CR Makhson A D'Haens G Pintér T Lim R Bodoky G Roh JK Folprecht G Ruff P Stroh C Tejpar S Schlichting M Nippgen J Rougier P Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 2009, 360:1408-07. 10.1056/NEJMoa0805019 19339720
8. Lievre A Bachet JB Boige V Cayre A Le Corre D Buc E Ychou M Bouché O Landi B Louvet C André T Bibeau F Diebold MD Rougier P Ducreux M Tomasic G Emile JF Penault-Llorca F Laurent-Puig P Kras Mutation as an indipendent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 2008, 28:374-379. 10.1200/JCO.2007.12.5906
9. Di Fiore F Blanchard F Charbonnier F Le Pessot F Lamy A Galais MP Bastit L Killian A Sesboüé R Tuech JJ Queuniet AM Paillot B Sabourin JC Michot F Michel P Frebourg T Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 2007, 96:1166-1169. 10.1038/sj.bjc.6603685 17375050
10. Khambata-Ford S Garrett CR Meropol NJ Basik M Harbison CT Wu S Wong TW Huang X Takimoto CH Godwin AK Tan BR Krishnamurthi SS Burris HA 3rd Poplin EA Hidalgo M Baselga J Clark EA Mauro DJ Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab J Clin oncol 2007, 25:3230-3236. 10.1200/JCO.2006.10.5437 17664471
11. De Roock W Piessevaux H De Schutter J Janssens M De Hertogh G Personeni N Biesmans B Van Laethem JL Peeters M Humblet Y Van Cutsem E Tejpar S KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 2008, 19:508-515. 10.1093/annonc/mdm496 17998284
12. Benvenuti S Sartore-Bianchi A Di Nicolantonio F Zanon C Moroni M Veronese S Siena S Bardelli A Oncogenetic activation of RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 2007, 67:2643-2648. 10.1158/0008-5472.CAN-06-4158 17363584
13. Moroni M Veronese S Benvenuti S Marrapese G Sartore-Bianchi A Di Nicolantonio F Gambacorta M Siena S Bardelli A Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study Lancet Oncology 2005, 5:279-286. 10.1016/S1470-2045(05)70102-9
14. Sartore-Bianchi A Moroni M Veronese S Carnaghi C Bajetta E Luppi G Sobrero A Barone C Cascinu S Colucci G Cortesi E Nichelatti M Gambacorta M Siena S Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 2007, 25:3238-45. 10.1200/JCO.2007.11.5956 17664472
15. Cappuzzo F Finocchiaro G Rossi E Jänne PA Carnaghi C Calandri C Bencardino K Ligorio C Ciardiello F Pressiani T Destro A Roncalli M Crino L Franklin WA Santoro A Varella-Garcia M EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 2008, 19:717-23. 10.1093/annonc/mdm492 17974556
16. Isola J Tanner M Chromogenic in situ hybridization in tumor pathology Methods Mol Med 2004, 97:133-144. 15064490
17. Tanner M Gancher D Di Leo A Larsimont D Rouas G Piccart MJ Isola J Chromogenic in situ hybridization: A practical alternative for fluorescent in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples Am J pathol 2000, 157:1467-1472. 1885742 11073807
18. Hanna WM Kwok K Chromogenic in situ hybridization: A viable alternative to fluorescent in situ hybridization in the HER-2 testing algorithm Mod Pathol 2006, 19:481-487. 10.1038/modpathol.3800555 16444193
19. Sholl LM Iafrate AJ Chou YP Wu MT Goan YG Su L Huang YT Su L Huang YT Christiani DC Chirieac LR Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in non small cell lung carcinoma Mod Pathol 2007, 20:1028-1035. 10.1038/ modpathol.3800946 17673923
20. Shia J Klimstra DS Ri AR Qin J Saltz L Teruya-Feldstein J Akram M Chung KY Yao D Paty PB Gerald W Chen B Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study Mod Pathol 2005, 16:1-7.
21. Scartozzi M Bearzi I Pierantoni C Mandolesi A Loupakis F Zaniboni A Catalano V Quadri A Zorzi F Berardi R Biscotti T Labianca R Falcone A Cascinu S Nuclear Factor kB tumor expression predicts response and survival in irinotecan refractory metastatic colorectal cancer patients treated with cetuximab irinotecan therapy J Clin Oncol 2007, 26:3930-3935. 10.1200/JCO.2007.11.5022